SIRT1 and glucose metabolism disease: Studies have shown that catalpol ameliorates triptolide-induced hepatic glucose metabolism disorders and oxidative stress through the modulation of the Sirtuin 1 (SIRT1)/Hypoxia-Inducible Factor-1α (HIF-1α) signaling pathway (Nie et al., 2024).